5 Biotech Stocks On Deck With The FDA

Some traders like to gamble on big news events that could have a dramatic effect on a particular stock. For example, the release of a company’s earnings report could cause an underlying stock to jump to new highs or drop to significant lows. While this may not interest all investors, it does prove to be a point of intrigue for some traders.

Unfortunately, earnings season comes and goes. However, thanks to the biotechnology industry, there are stocks with major news events coming out all the time.

In addition to the same earnings releases, FDA announcements are commonplace and can cause major pops and drops for underlying stocks.

Here are a few biotech stocks with possible FDA announcements coming up soon.

Alnylam Pharmaceuticals, Inc. ALNY

 

 

Phase 2 open label data of Patisiran for Familial Amyloidotic Polyneuropathy in patients with ATTR due mid-2015.

The stock closed recently at $114.21/share.

Esperion Therapeutics Inc ESPR

 

 

Phase 2 data of ETC-1002-014 for hypercholesterolemia and hypertension due mid-2015.

Esperion closed at $78.28/share Monday.

Related Link: Greek Crisis: An Opportunity To Buy Europe, Biotech And SMID-Cap Discretionary

Intercept Pharmaceuticals Inc ICPT

 

 

Completion of NDA filing of Obeticholic acid for primary biliary cirrhosis planned in Q2 of 2015.

On Monday, the stock closed at $240.39/share.

Sarepta Therapeutics, Inc. SRPT

 

 

Rolling NDA filing of Eteplirsen for Duchenne muscular dystrophy to be completed mid-2015.

Sarepta finished the day Monday at $28.18/share.

Tekmira Pharmaceuticals Corp TKMR

 

 

Phase 1/2 final data of TKM-PLK1 for gastrointestinal neuroendocrine tumors due mid-2015.

Tekmira closed recently at $11.81/share.

Final Notes

All data has been obtained from BioPharmCatalyst.

Investors must conduct their own due diligence before investing in any stock, but whether one is looking to avoid or capitalize on news events, the biotechs should be names to watch.

Image Credit: Public Domain